Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
AD/PD 2026 | Copenhagen, Denmark
Mar 17 - 21, 2026
Poster
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants With Parkinson’s DiseaseAACR RAS 2026 | Los Angeles, CA
Mar 5 - 8, 2026
Poster
Preclinical Activity of an Orally Bioavailable PROTAC Pan-KRAS Degrader Versus Inhibitors in Mutant KRAS ModelsAACR RAS 2026 | Los Angeles, CA
Mar 5 - 8, 2026
Presentation
Preclinical Activity of an Orally Bioavailable PROTAC Pan-KRAS Degrader Versus Inhibitors in Mutant KRAS ModelsAACR IO 2026 | Los Angeles, CA
Feb 18 - 21, 2026
Poster
Antitumor and Immunomodulatory Activity of ARV-6723, a PROTAC HPK1 Degrader, Across High- and Low-Immunogenic Solid TumorsASCO GI 2026 | San Francisco, CA
Jan 8 - 10, 2026
Poster
Phase 1/2 Study of ARV-806, a PROTAC KRAS G12D Degrader, in KRAS G12D-mutated Advanced Solid Tumors, including Pancreatic CancerSABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Circulating Tumor DNA Biomarker Analyses of a Phase 1/2 Study Evaluating Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in ER+/HER2- Advanced Breast CancerSABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Real-world Prevalence of ESR1 Mutations Among Patients With ER+/HER2- Metastatic Breast Cancer After First-line Treatment With Endocrine Therapy and/or a CDK4/6 InhibitorSABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Subgroup Analyses of VERITAC-2: A Phase 3 Trial of Vepdegestrant, a PROTAC ER Degrader, vs Fulvestrant in ER+/HER2- Advanced Breast CancerASH 2025 | Orlando, FL
Dec 6 - 9, 2025